LT3150198T - 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas - Google Patents

3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas

Info

Publication number: LT3150198T
Authority: LT; Lithuania
Prior art keywords: cycloproparboxamide; difluorbenzo; dioxol; methylpyridin; introduction
Prior art date: 2010-04-07

Application number

LTEP16185289.2T

Other languages

English (en)

Inventor

Marinus VERWIJS

Rossitza Alargova

Ritu Kaushik

Irina Kadiyala

Christopher Young

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-07

Filing date

2011-04-07

Publication date

2021-12-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47075277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3150198(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-07 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2021-12-10 Publication of LT3150198T publication Critical patent/LT3150198T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Cardiology (AREA)

LTEP16185289.2T 2010-04-07 2011-04-07 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas LT3150198T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US32172910P	2010-04-07	2010-04-07
US32174810P	2010-04-07	2010-04-07
US36656210P	2010-07-22	2010-07-22

Publications (1)

Publication Number	Publication Date
LT3150198T true LT3150198T (lt)	2021-12-10

Family

ID=47075277

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP16185289.2T LT3150198T (lt)	2010-04-07	2011-04-07	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas

Country Status (25)

Country	Link
US (8)	US8552034B2 (lt)
EP (3)	EP4005559B1 (lt)
JP (3)	JP2013523833A (lt)
CN (3)	CN106943403A (lt)
AR (1)	AR081760A1 (lt)
AU (1)	AU2011237601B2 (lt)
BR (1)	BR112012026255A2 (lt)
CA (1)	CA2795804C (lt)
CY (1)	CY1124852T1 (lt)
DK (1)	DK3150198T3 (lt)
ES (3)	ES3017582T3 (lt)
HR (1)	HRP20211752T1 (lt)
HU (1)	HUE056525T2 (lt)
IL (2)	IL222314A (lt)
LT (1)	LT3150198T (lt)
MX (2)	MX364937B (lt)
NZ (2)	NZ708598A (lt)
PL (1)	PL3150198T3 (lt)
PT (1)	PT3150198T (lt)
RS (1)	RS62767B1 (lt)
RU (1)	RU2592368C2 (lt)
SI (1)	SI3150198T1 (lt)
SM (1)	SMT202100670T1 (lt)
WO (1)	WO2011127241A2 (lt)
ZA (1)	ZA201208225B (lt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004272599A1 (en)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7495103B2 (en)	2004-06-24	2009-02-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CA2618057A1 (en)	2005-08-11	2007-02-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
DK2395002T3 (da) *	2005-11-08	2014-09-08	Vertex Pharma	Farmaceutisk sammensætning indeholdende en heterocyclisk modulator af ATP-bindende kassettetransportører
NZ569327A (en)	2005-12-28	2011-09-30	Vertex Pharma	1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
CA2635581C (en)	2005-12-28	2017-02-28	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
SI2007756T1 (sl)	2006-04-07	2015-11-30	Vertex Pharmaceuticals Incorporated	Modulatorji prenašalcev z atp-vezavno kaseto
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CN102863432B (zh)	2007-05-09	2016-09-07	沃泰克斯药物股份有限公司	Cftr调节剂
CN101827593B (zh)	2007-08-24	2013-07-24	沃泰克斯药物股份有限公司	用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
AU2008322616B2 (en)	2007-11-16	2013-07-18	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-Binding Cassette transporters
SG186638A1 (en)	2007-12-07	2013-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
MX2010006183A (es)	2007-12-07	2010-10-15	Vertex Pharma	Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
CA2708146A1 (en) *	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ703814A (en)	2008-02-28	2016-06-24	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
MX2011003249A (es)	2008-09-29	2011-05-19	Vertex Pharma	Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
SMT201700593T1 (it)	2009-03-20	2018-03-08	Vertex Pharma	Procedimento per preparare modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ602795A (en)	2010-04-07	2015-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN106943403A (zh)	2010-04-07	2017-07-14	弗特克斯药品有限公司	药物组合物和其给药方法
MX2012012204A (es)	2010-04-22	2012-12-05	Vertex Pharma	Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
ME02650B (me)	2011-11-08	2017-06-20	Vertex Pharma	Modulatori atp- vezujućih kasetnih transportera
PL2806859T3 (pl) *	2012-01-25	2019-11-29	Vertex Pharma	Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
WO2013139695A1 (en)	2012-03-22	2013-09-26	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013185112A1 (en) *	2012-06-08	2013-12-12	Vertex Pharmaceuticals Incorporated	Pharmaceuticl compositions for the treatment of cftr -mediated disorders
HK1209318A1 (en)	2012-07-16	2016-04-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SMT201800590T1 (it) *	2012-11-02	2019-01-11	Vertex Pharma	Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
AU2014243818B2 (en)	2013-03-13	2017-04-20	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
AU2014302458A1 (en) *	2013-06-26	2015-12-24	Proteostasis Therapeutics, Inc.	Methods of modulating CFTR activity
PT3068392T (pt)	2013-11-12	2021-05-14	Vertex Pharma	Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
NO2699580T3 (lt)	2014-01-24	2018-02-24
DK3925607T3 (da)	2014-04-15	2023-08-21	Vertex Pharma	Farmaceutiske sammensætninger til behandlingen af cystisk fibrosetransmembrankonduktansregulator-medierede sygdomme
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
KR102336926B1 (ko)	2014-10-06	2021-12-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제
CA2963945C (en)	2014-10-07	2023-01-10	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107110831B (zh)	2014-11-18	2020-02-21	弗特克斯药品有限公司	进行高通量试验高效液相色谱的方法
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
CN105130949B (zh) *	2015-09-02	2019-01-29	阜新奥瑞凯新材料有限公司	1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法
US10759721B2 (en)	2015-09-25	2020-09-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
CN105218510B (zh) *	2015-10-23	2017-09-15	上海平创化工科技有限公司	一种2,2‑二氟‑5‑氯甲基胡椒环的制备方法
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2018037350A1 (en) *	2016-08-23	2018-03-01	Laurus Labs Limited	Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
UA124708C2 (uk)	2016-09-30	2021-11-03	Вертекс Фармасьютікалз Інкорпорейтед	Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
AU2017371200B2 (en)	2016-12-09	2021-05-06	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN116730921A (zh)	2017-02-17	2023-09-12	文涵治疗有限公司	Ag-10的制备方法、其中间体及其盐
MA54105A (fr)	2017-06-08	2021-09-15	Vertex Pharma	Méthodes de traitement de la fibrose kystique
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
KR102606188B1 (ko)	2017-08-02	2023-11-23	버텍스 파마슈티칼스 인코포레이티드	피롤리딘 화합물을 제조하기 위한 공정
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
WO2019109021A1 (en)	2017-12-01	2019-06-06	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US11465985B2 (en)	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CN107982260A (zh) *	2017-12-12	2018-05-04	南京市儿童医院	VX-809在制备治疗Bartter综合征药物中的应用
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
RS64018B1 (sr)	2018-02-15	2023-03-31	Vertex Pharma	Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
CN112055593B (zh) *	2018-03-01	2024-04-09	阿斯利康(瑞典)有限公司	药物组合物
SG11202009073WA (en)	2018-03-23	2020-10-29	Eidos Therapeutics Inc	Methods of treating ttr amyloidosis using ag10
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3823627A4 (en)	2018-07-17	2022-04-20	Insmed Incorporated	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
EP3836920B1 (en) *	2018-08-17	2025-10-01	Eidos Therapeutics, Inc.	Formulations of ag10
BR112021009145A2 (pt)	2018-11-14	2021-08-10	Vertex Pharmaceuticals Incorporated	métodos de tratamento para fibrose cística
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
MX2022001828A (es)	2019-08-14	2022-06-08	Vertex Pharma	Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202207940A (zh) *	2020-04-14	2022-03-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2021253380A1 (en) *	2020-06-19	2021-12-23	InventisBio Co., Ltd.	Oral formulations and uses thereof
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
MX2023001438A (es) *	2020-08-04	2023-06-15	Calcilytix Therapeutics Inc	Formulaciones de compuestos calciliticos de trifenilo.
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023006770A (es)	2020-12-10	2023-08-14	Vertex Pharma	Metodos de tratamiento para fibrosis quistica.
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
KR20250065916A (ko)	2022-09-15	2025-05-13	이도르시아 파마슈티컬스 리미티드	마크로시클릭 cftr 조절제와 cftr 교정제 및/또는 cftr 강화제의 조합
JP2025531206A (ja)	2022-09-15	2025-09-19	イドルシア・ファーマシューティカルズ・リミテッド	大環状ｃｆｔｒ調節剤
AU2024206233A1 (en)	2023-01-06	2025-08-21	Insmed Incorporated	Novel, reversible dpp1 inhibitors and uses thereof
WO2025186214A1 (en)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758475A (en)	1971-07-20	1973-09-11	Sandoz Ag	Pyrido(2,3-d)pyrimidin 2 ones
IT1226048B (it)	1981-12-14	1990-12-10	Medea Res Srl	Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
EP0081756B1 (en)	1981-12-14	1985-05-15	MEDEA RESEARCH S.r.l.	New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
US4501729A (en)	1982-12-13	1985-02-26	Research Corporation	Aerosolized amiloride treatment of retained pulmonary secretions
US4844908A (en) *	1986-11-27	1989-07-04	Duphar International Research B.V.	Method of preparing tablets with clovoxamine fumarate and tablets thus prepared
US5981714A (en)	1990-03-05	1999-11-09	Genzyme Corporation	Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja)	1990-11-27	2001-05-21	武田薬品工業株式会社	ピリドピリダジン誘導体およびその用途
US5612360A (en)	1992-06-03	1997-03-18	Eli Lilly And Company	Angiotensin II antagonists
CA2107196A1 (en)	1992-09-29	1994-03-30	Mitsubishi Chemical Corporation	Carboxamide derivatives
US6060024A (en)	1993-07-14	2000-05-09	Zymark Corporation	Automatic dissolution testing system
GB9317764D0 (en)	1993-08-26	1993-10-13	Pfizer Ltd	Therapeutic compound
KR100342275B1 (ko)	1993-10-21	2002-12-05	지.디. 썰 엘엘씨	산화질소신타제저해제로서유용한아미디노유도체
DE4405712A1 (de)	1994-02-23	1995-08-24	Basf Ag	Substituierte Naphthyridine und deren Verwendung
CA2146701A1 (en)	1994-04-11	1995-10-12	Takashi Fujita	Heterocyclic compounds having anti-diabetic activity, their preparation and their use
ES2141383T3 (es)	1994-09-27	2000-03-16	Janssen Pharmaceutica Nv	Derivados de benzoatos biciclicos de piperidinilo sustituido en n.
ES2171542T3 (es)	1994-10-28	2002-09-16	Sophion Bioscience As	Aparato y tecnica de patch-clamp que tienen alta produccion y que requieren un pequeño volumen de fluido.
US5656256A (en)	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en)	1994-12-19	1996-04-23	Warner-Lambert Company	Sulfonate ACAT inhibitors
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
DE19531067A1 (de) *	1995-08-23	1997-02-27	Hermann P T Prof Dr Med Ammon	Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
AU715658B2 (en)	1996-04-03	2000-02-10	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CA2268051A1 (en)	1996-08-23	1998-02-26	Alanex Corporation	Neuropeptide-y ligands
EP1003374A4 (en)	1996-12-30	2000-05-31	Merck & Co Inc	INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
CO4920215A1 (es)	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5948814A (en)	1997-02-20	1999-09-07	The Curators Of The University Of Missouri	Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en)	1997-04-18	1998-10-29	Smithkline Beecham Plc	Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
BR9813019A (pt)	1997-10-02	2000-09-05	Sankyo Co	Derivados do ácido amidocarboxìlico, agentes para diminuir a glicose do sangue, redutor de lipìdio, para melhorar a resistência à insulina, anti-inflamatório, para imuno regulagem, para inibir a aldose reductase, para inibir a 5-lipoxigenase, para a geração de supressor de peróxido de lipìdio, para ativar a ppar, para minorar a osteoporose, e, composições para a terapia ou prevenção da diabete melito, da hiperlipemia, da obesidade, da tolerância à glicose prejudicada, da resistência à insulina que não a igt, do fìgado gorduroso, de complicações diabéticas, da arterioesclerose, da diabete melito gestacional, da sìndrome do ovário policìstico, da artroesteìte, da artrite reumática, de doenças alérgicas, da asma, do câncer, de doenças auto imunes, da pancreatite, e de cataratas
ES2216495T3 (es)	1998-02-17	2004-10-16	G.D. SEARLE & CO.	Procedimiento para la resolucion enzimatica de lactamas.
WO1999064394A1 (en)	1998-06-08	1999-12-16	Schering Corporation	Neuropeptide y5 receptor antagonists
US6426331B1 (en)	1998-07-08	2002-07-30	Tularik Inc.	Inhibitors of STAT function
AUPP609198A0 (en)	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
CA2347770A1 (en)	1998-12-18	2000-06-22	Bristol-Myers Squibb Pharma Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ES2226622T3 (es)	1999-02-24	2005-04-01	F. Hoffmann-La Roche Ag	Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
BR0008489A (pt)	1999-02-24	2002-02-05	Hoffmann La Roche	Derivados de fenil- e piridinila
JP4068305B2 (ja)	1999-02-24	2008-03-26	エフ．ホフマン−ラロシュアーゲー	３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CN1356988A (zh)	1999-06-18	2002-07-03	拜尔公司	苯氧基氟代嘧啶类化合物
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en)	1999-12-16	2001-06-28	Novartis Ag	N-heteroaryl-amides and their use as parasiticides
CA2396079A1 (en)	2000-01-07	2001-07-19	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
EP1253923A1 (en)	2000-01-28	2002-11-06	Biogen, Inc.	Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en)	2000-02-01	2001-08-09	Cor Therapeutics, Inc.	Inhibitors of factor xa
AU2001249417A1 (en)	2000-04-26	2001-11-07	Gliatech, Inc.	Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2001083517A1 (en)	2000-05-03	2001-11-08	Tularik Inc.	Stat4 and stat6 binding dipeptide derivatives
US6499984B1 (en)	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
WO2001092235A1 (en)	2000-06-01	2001-12-06	Bristol-Myers Squibb Pharma Company	LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
ES2242771T5 (es)	2000-09-15	2011-10-14	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol útiles como inhibidores de proteína quinasas.
JP4272338B2 (ja)	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
US20020115619A1 (en) *	2000-10-04	2002-08-22	Rubenstein Ronald C.	Compositions and methods for treatment of cystic fibrosis
GB2367816A (en)	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
AU2002212282A1 (en)	2000-10-20	2002-05-06	Merck Patent G.M.B.H	Chiral binaphthol derivatives
US6884782B2 (en)	2000-11-08	2005-04-26	Amgen Inc.	STAT modulators
WO2002044183A2 (en)	2000-12-01	2002-06-06	Guilford Pharmaceuticals Inc.	Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
GB0102687D0 (en)	2001-02-02	2001-03-21	Pharmacia & Upjohn Spa	Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
US6962674B2 (en)	2001-02-28	2005-11-08	Varian, Inc.	Dissolution test apparatus
AU2002258794A1 (en)	2001-04-10	2003-10-20	Transtech Pharma, Inc.	Probes, systems and methods for drug discovery
MXPA03009720A (es)	2001-04-23	2004-01-29	Hoffmann La Roche	USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
PL367153A1 (en)	2001-05-22	2005-02-21	Neurogen Corporation	5-substituted-2-arylpyridines as crf1 modulators
US20030083345A1 (en)	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en)	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
US20030144350A1 (en)	2001-07-20	2003-07-31	Adipogenix, Inc.	Fat accumulation-modulation compounds
EP1411928A1 (en)	2001-07-20	2004-04-28	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
US7427623B2 (en)	2001-09-11	2008-09-23	Smithkline Beecham Corporation	4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja)	2001-11-19	2003-05-27	Toray Ind Inc	環状含窒素誘導体
JP2003221386A (ja)	2001-11-26	2003-08-05	Takeda Chem Ind Ltd	二環性誘導体、その製造法およびその用途
PL370989A1 (en)	2001-12-21	2005-06-13	Novo Nordisk A/S	Amide derivatives as gk activators
TW200307539A (en)	2002-02-01	2003-12-16	Bristol Myers Squibb Co	Cycloalkyl inhibitors of potassium channel function
TW200304820A (en)	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr)	2002-06-12	2005-03-11		Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
PL374971A1 (en)	2002-08-09	2005-11-14	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
CN100356922C (zh)	2002-09-30	2007-12-26	加利福尼亚大学董事会	囊性纤维化跨膜传导调节因子蛋白抑制剂及其用途
WO2004035571A1 (en)	2002-10-15	2004-04-29	Rigel Pharmaceuticals, Inc.	Substituted indoles and their use as hcv inhibitors
EP1558576A4 (en)	2002-10-30	2008-04-16	Merck & Co Inc	PIPERIDINYLCYCLOPENTYLARYLBENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTORACTIVITY
AU2003287449A1 (en)	2002-10-31	2004-05-25	Nanostream, Inc.	Parallel detection chromatography systems
US7910030B2 (en)	2002-11-26	2011-03-22	Universiteit Gent	Process and apparatus for continuous wet granulation of powder material
WO2004054505A2 (en)	2002-12-12	2004-07-01	Pharmacia Corporation	Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
CA2509086C (en)	2003-01-06	2012-08-21	Eli Lilly And Company	Substituted arylcyclopropylacetamides as glucokinase activators
AU2004212494B2 (en)	2003-02-10	2011-03-17	Vertex Pharmaceuticals Incorporated	Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
ES2770035T3 (es)	2003-04-11	2020-06-30	Ptc Therapeutics Inc	Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
CN1812977A (zh)	2003-04-30	2006-08-02	药物研发有限责任公司	取代羧酸
WO2004110352A2 (en)	2003-05-16	2004-12-23	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2530075C (en)	2003-06-27	2012-08-21	Harvey Pollard	Amphiphilic pyridinium compounds, method of making and use thereof
GB0315111D0 (en)	2003-06-27	2003-07-30	Cancer Rec Tech Ltd	Substituted 5-membered ring compounds and their use
JP2005053902A (ja)	2003-07-18	2005-03-03	Nippon Nohyaku Co Ltd	フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
JP2007504271A (ja)	2003-09-05	2007-03-01	ニューロジェン・コーポレーション	Ｃｒｆ１受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類
AU2004272599A1 (en)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20050070718A1 (en)	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP2007509044A (ja)	2003-10-08	2007-04-12	バーテックス　ファーマシューティカルズ　インコーポレイテッド	シクロアルキルピラニル基を含むａｔｐ結合カセットトランスポーターのモジュレータ
WO2005037269A1 (ja)	2003-10-21	2005-04-28	Dainippon Sumitomo Pharma Co., Ltd.	新規ピペリジン誘導体
FR2861304B1 (fr)	2003-10-23	2008-07-18	Univ Grenoble 1	Modulateurs des canaux cftr
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
RU2006120549A (ru)	2003-11-14	2007-12-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
JP2007511572A (ja)	2003-11-19	2007-05-10	グラクソ　グループ　リミテッド	統合失調症治療のためのシクロオキシゲナーゼ−２選択的阻害剤の使用
JP3746062B2 (ja) *	2003-12-05	2006-02-15	第一製薬株式会社	固形製剤およびその製造方法
ES2238001B1 (es)	2004-01-21	2006-11-01	Vita Cientifica, S.L.	Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN1938279B (zh)	2004-01-30	2011-09-14	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白调控剂
US7522995B2 (en)	2004-02-05	2009-04-21	Nortrup Edward H	Method and system for providing travel time information
CA2555409A1 (en)	2004-02-19	2005-09-01	Banyu Pharmaceutical Co., Ltd.	Novel sulfone amide derivative
EP1740532A4 (en)	2004-03-30	2009-06-10	Univ California	CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
WO2005115399A2 (en)	2004-04-16	2005-12-08	Neurogen Corporation	Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
EP1740575A2 (en)	2004-04-22	2007-01-10	Eli Lilly And Company	Pyrrolidine derivatives useful as bace inhibitors
US7585885B2 (en)	2004-04-22	2009-09-08	Eli Lilly And Company	Pyrrolidine derivatives useful as BACE inhibitors
WO2005117514A2 (en) *	2004-06-01	2005-12-15	Tm Bioscience Corporation	Method of detecting cystic fibrosis associated mutations
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
TWI547431B (zh)	2004-06-09	2016-09-01	史密斯克萊美占公司	生產藥物之裝置及方法
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
US20140343098A1 (en)	2004-06-24	2014-11-20	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7495103B2 (en)	2004-06-24	2009-02-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
WO2006003504A1 (en)	2004-07-01	2006-01-12	Warner-Lambert Company Llc	Preparation of pharmaceutical compositions containing nanoparticles
EP1771158A4 (en)	2004-07-02	2008-03-12	Advancis Pharmaceutical Corp	TABLET FOR PULSE DISTRIBUTION
US8188277B2 (en)	2004-08-06	2012-05-29	Otsuka Pharmaceutical Co., Ltd.	Aromatic compounds for suppressing the generation of collagen
AU2005289426A1 (en)	2004-09-27	2006-04-06	Amgen Inc.	Substituted heterocyclic compounds and methods of use
BRPI0516093A (pt)	2004-10-12	2008-08-19	Astrazeneca Ab	derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
JP2008515992A (ja)	2004-10-13	2008-05-15	ピーティーシーセラピューティクス，インコーポレーテッド	体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用
JP5036126B2 (ja) *	2004-10-19	2012-09-26	日医工株式会社	エバスチン経口投与用製剤
WO2006051394A1 (en)	2004-11-15	2006-05-18	Pfizer Products Inc.	Azabenzoxazoles for the treatment of cns disorders
DK1856031T3 (da)	2004-12-15	2009-06-29	Dompe Pha R Ma Spa Res & Mfg	2-arylpropionsyrederivater og farmaceutiske sammensætninger indeholdende disse
JP4790260B2 (ja)	2004-12-22	2011-10-12	出光興産株式会社	アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
EP1844003A4 (en)	2005-01-27	2010-09-22	Astrazeneca Ab	NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en)	2005-01-28	2011-02-15	Abbott Laboratories	Inhibitors of c-jun N-terminal kinases
WO2006082952A1 (ja)	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	アミド化合物
WO2006099256A2 (en)	2005-03-11	2006-09-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
AU2006227833A1 (en)	2005-03-18	2006-09-28	The Regents Of The University Of California	Compounds having activity in correcting mutant-CFTR processing and uses thereof
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI377206B (en)	2005-04-06	2012-11-21	Theravance Inc	Crystalline form of a quinolinone-carboxamide compound
CA2603402C (en)	2005-04-08	2017-10-31	Ptc Therapeutics, Inc.	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP1710246A1 (en)	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
TW200716594A (en)	2005-04-18	2007-05-01	Neurogen Corp	Substituted heteroaryl CB1 antagonists
JP2008536947A (ja)	2005-04-19	2008-09-11	バイエル・フアーマシユーチカルズ・コーポレーシヨン	アリールアルキル酸誘導体およびそれらの使用
AU2006240247A1 (en)	2005-04-20	2006-11-02	Merck Sharp & Dohme Corp.	Angiotensin II receptor antagonists
CN101163689A (zh)	2005-04-22	2008-04-16	惠氏公司	{[(2r)-7-(2，6-二氯苯基)-5-氟-2，3-二氢-1-苯并呋喃-2-基]甲基}胺盐酸盐的晶形
CN1864679A (zh) *	2005-05-16	2006-11-22	马晶	一种复方岩白菜素分散片及其制备方法
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
JP5426878B2 (ja)	2005-05-24	2014-02-26	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ−結合カセットトランスポーターのモジュレーター
JP2008545744A (ja)	2005-06-02	2008-12-18	バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト	フェニルアルキル置換ヘテロアリール誘導体
WO2006136829A2 (en)	2005-06-21	2006-12-28	Astex Therapeutics Limited	Pyrazole derivatives and their use as pka and pkb modulators
US20070027451A1 (en) *	2005-06-23	2007-02-01	Kai Desinger	Method for treatment of hypertrophic palatine tonsils
CN101287732A (zh)	2005-08-11	2008-10-15	沃泰克斯药物股份有限公司	囊性纤维化跨膜电导调节剂的调控剂
CA2618057A1 (en)	2005-08-11	2007-02-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN101305011B (zh)	2005-09-09	2011-03-02	史密丝克莱恩比彻姆公司	吡啶衍生物及其在治疗精神障碍中的用途
RU2431473C2 (ru)	2005-09-23	2011-10-20	Ф. Хоффманн-Ля Рош Аг	Новая лекарственная форма
AU2006302371A1 (en)	2005-10-06	2007-04-19	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
US8710233B2 (en)	2005-10-19	2014-04-29	Gruenenthal Gmbh	Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations
US20120232059A1 (en)	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
WO2007054480A1 (en)	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
DK2395002T3 (da)	2005-11-08	2014-09-08	Vertex Pharma	Farmaceutisk sammensætning indeholdende en heterocyclisk modulator af ATP-bindende kassettetransportører
US7807673B2 (en)	2005-12-05	2010-10-05	Glaxosmithkline Llc	2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
EP1979367A2 (en)	2005-12-24	2008-10-15	Vertex Pharmaceuticals Incorporated	Quinolin-4-one derivatives as modulators of abc transporters
EP1974212A1 (en)	2005-12-27	2008-10-01	Vertex Pharmaceuticals Incorporated	Compounds useful in cftr assays and methods therewith
NZ569327A (en)	2005-12-28	2011-09-30	Vertex Pharma	1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CA2635581C (en)	2005-12-28	2017-02-28	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8158059B2 (en)	2005-12-30	2012-04-17	Sotax Corporation	Integrated dissolution processing and sample transfer system
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
SI2007756T1 (sl)	2006-04-07	2015-11-30	Vertex Pharmaceuticals Incorporated	Modulatorji prenašalcev z atp-vezavno kaseto
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
AU2007249269A1 (en)	2006-05-12	2007-11-22	Vertex Pharmaceuticals Incorporated	Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
ES2646175T3 (es)	2006-11-03	2017-12-12	Vertex Pharmaceuticals Incorporated	Derivados de azaindol como moduladores de CFTR
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP5318400B2 (ja) *	2006-11-20	2013-10-16	第一三共株式会社	レボフロキサシン含有錠剤
CN101541759A (zh)	2006-11-27	2009-09-23	诺瓦提斯公司	取代的二氢咪唑类及其在治疗肿瘤中的用途
US20080260820A1 (en) *	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
MX2009011755A (es)	2007-05-02	2010-02-12	Portola Pharm Inc	Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
CN102863432B (zh)	2007-05-09	2016-09-07	沃泰克斯药物股份有限公司	Cftr调节剂
WO2008147952A1 (en)	2007-05-25	2008-12-04	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2009023509A2 (en)	2007-08-09	2009-02-19	Vertex Pharmaceuticals Incorporated	Therapeutic combinations useful in treating cftr related diseases
CN101827593B (zh)	2007-08-24	2013-07-24	沃泰克斯药物股份有限公司	用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
DE102007042754A1 (de)	2007-09-07	2009-03-12	Bayer Healthcare Ag	Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
AU2008298545B2 (en)	2007-09-14	2013-12-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
RU2010114732A (ru)	2007-09-14	2011-10-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
FR2921657A1 (fr)	2007-09-28	2009-04-03	Sanofi Aventis Sa	Derives de nicotinamide, leur preparation et leur application en therapeutique
AU2008322616B2 (en)	2007-11-16	2013-07-18	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-Binding Cassette transporters
CA2708146A1 (en) †	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SG186638A1 (en)	2007-12-07	2013-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
MX2010006183A (es)	2007-12-07	2010-10-15	Vertex Pharma	Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
ES2422741T3 (es)	2007-12-13	2013-09-13	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
NZ703814A (en)	2008-02-28	2016-06-24	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2257356B1 (en)	2008-02-29	2016-12-14	Waters Technologies Corporation	Chromatography-based monitoring and control of multiple process streams
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
EP2110377A1 (en)	2008-04-15	2009-10-21	DAC S.r.l.	Spirocyclic derivatives as histone deacetylase inhibitors
GB0813709D0 (en)	2008-07-26	2008-09-03	Univ Dundee	Method and product
HRP20180328T1 (hr)	2008-08-13	2018-04-20	Vertex Pharmaceuticals Inc.	FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US20100256184A1 (en)	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
MX2011003249A (es)	2008-09-29	2011-05-19	Vertex Pharma	Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
TWI465449B (zh)	2008-10-23	2014-12-21	Vertex Pharma	囊腫性纖維化跨膜傳導調節因子之調控因子
US20110257223A1 (en)	2008-10-23	2011-10-20	Vertex Pharmaceuticals Incorporated	Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
ES2406361T3 (es)	2008-10-23	2013-06-06	Vertex Pharmaceuticals Incorporated	Formas sólidas de la N-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-carboxamida
WO2010048564A1 (en)	2008-10-23	2010-04-29	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA2740836C (en)	2008-10-31	2017-03-21	Biomerieux, Inc.	Methods for separation, characterization and/or identification of microorganisms using spectroscopy
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
HRP20150288T1 (hr)	2008-11-06	2015-04-24	Vertex Pharmaceuticals Incorporated	Modulatori atp-vezujuä†ih kasetnih transportera
US8367660B2 (en)	2008-12-30	2013-02-05	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
RU2518897C2 (ru)	2009-03-20	2014-06-10	Вертекс Фармасьютикалз Инкорпорейтед	Производные 3-карбоксамида-4-оксохинолина, полезные в качестве модуляторов регулятора трансмембранной проводимости кистозного фиброза
SMT201700593T1 (it)	2009-03-20	2018-03-08	Vertex Pharma	Procedimento per preparare modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
DK2427166T3 (da)	2009-05-07	2014-01-27	Gea Pharma Systems Ltd	Tabletfremstillingsmodul og fremgangsmåde til kontinuerlig fremstilling af tabletter
US8404865B2 (en)	2009-09-17	2013-03-26	Vertex Pharmaceuticals	Process for preparing azabicyclic compounds
JP2013508414A (ja)	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症および他の慢性疾患の治療のための組成物
BR112012009584A2 (pt)	2009-10-23	2019-09-24	Vertex Pharma	formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluorometil)fenil)-4-oxo-5-(trifluorometil)-1,4-di-hidroquinolina-3-carboxamida
US8344147B2 (en)	2009-10-23	2013-01-01	Vertex Pharmaceutical Incorporated	Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
AU2011227021A1 (en)	2010-03-19	2012-10-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN106083832A (zh)	2010-03-25	2016-11-09	弗特克斯药品有限公司	(r)‑1(2,2‑二氟苯并[d][1,3]间二氧杂环戊烯‑5‑基)‑n‑(1‑(2,3‑二羟基丙基)‑6‑氟‑2‑(1‑羟基‑2‑甲基丙‑2‑基)‑1h‑吲哚‑5‑基)环丙烷甲酰胺的固体形式
NZ602795A (en)	2010-04-07	2015-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN106943403A (zh)	2010-04-07	2017-07-14	弗特克斯药品有限公司	药物组合物和其给药方法
MX2012012204A (es)	2010-04-22	2012-12-05	Vertex Pharma	Proceso para producir compuestos de cicloalquilcarboxamido-indol.
EP2560650A1 (en)	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
WO2011133951A1 (en)	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
NZ603044A (en) *	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
AU2011255237A1 (en)	2010-05-20	2012-11-29	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
AR081920A1 (es)	2010-05-20	2012-10-31	Vertex Pharma	Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh)	2010-08-23	2013-06-12	弗特克斯药品有限公司	(R)-1-(2，2-二氟苯并[d][1，3]间二氧杂环戊烯-5-基)-N-(1-(2，3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
CA2809263A1 (en)	2010-08-27	2012-03-01	Eleni Dokou	Pharmaceutical composition and administrations thereof
CN102058889A (zh)	2010-11-05	2011-05-18	王定豪	包含抗凝血类药物的分散片及其应用
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN102507770A (zh)	2011-10-25	2012-06-20	中国检验检疫科学研究院	检测化妆品中六氯酚的高效液相色谱法
EP2773349A1 (en)	2011-11-02	2014-09-10	Vertex Pharmaceuticals Incorporated	Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
US20140127901A1 (en)	2012-11-08	2014-05-08	Taiwan Semiconductor Manufacturing Company, Ltd.	Low-k damage free integration scheme for copper interconnects
ME02650B (me)	2011-11-08	2017-06-20	Vertex Pharma	Modulatori atp- vezujućih kasetnih transportera
PL2806859T3 (pl)	2012-01-25	2019-11-29	Vertex Pharma	Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2013253790A (ja)	2012-06-05	2013-12-19	Chube Univ	ニバレノールの分析法
WO2013185112A1 (en)	2012-06-08	2013-12-12	Vertex Pharmaceuticals Incorporated	Pharmaceuticl compositions for the treatment of cftr -mediated disorders
HK1209318A1 (en)	2012-07-16	2016-04-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
US20140092376A1 (en)	2012-10-01	2014-04-03	Momentive Performance Materials, Inc.	Container and method for in-line analysis of protein compositions
SMT201800590T1 (it)	2012-11-02	2019-01-11	Vertex Pharma	Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
US9636301B2 (en)	2012-12-04	2017-05-02	Arbutus Biopharma Corporation	In vitro release assay for liposome encapsulated vincristine
US20140221424A1 (en)	2013-01-30	2014-08-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN103743826B (zh)	2013-08-28	2015-12-02	合肥久诺医药科技有限公司	一种阿齐沙坦的高效液相色谱分析方法
CN103822976B (zh)	2013-10-15	2015-05-27	辽宁省食品药品检验所	一种测定化妆品中4-甲氧基水杨酸钾的方法
PT3068392T (pt)	2013-11-12	2021-05-14	Vertex Pharma	Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
DK3925607T3 (da)	2014-04-15	2023-08-21	Vertex Pharma	Farmaceutiske sammensætninger til behandlingen af cystisk fibrosetransmembrankonduktansregulator-medierede sygdomme
CN104090038B (zh)	2014-07-07	2015-09-30	黄宏南	一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法
CN104122346B (zh)	2014-07-31	2016-03-16	国家烟草质量监督检验中心	一种水基胶中尿素含量的测定方法
CN104122345B (zh)	2014-07-31	2015-08-12	国家烟草质量监督检验中心	烟用纸中1,1,1-三羟甲基丙烷的测定方法
KR102336926B1 (ko)	2014-10-06	2021-12-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제
CA2963945C (en)	2014-10-07	2023-01-10	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107110831B (zh)	2014-11-18	2020-02-21	弗特克斯药品有限公司	进行高通量试验高效液相色谱的方法
WO2016086136A1 (en)	2014-11-26	2016-06-02	Catabasis Pharmaceuticals, Inc.	Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr)	2014-11-26	2017-10-03	Catabasis Pharmaceuticals Inc	Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016087665A2 (en)	2014-12-05	2016-06-09	Centre National De La Recherche Scientifique (Cnrs)	Compounds for treating cystic fibrosis
EP3250565B1 (en)	2015-01-26	2019-07-03	Rigel Pharmaceuticals, Inc.	Tetrazolones as carboxylic acid bioisosteres
UY36680A (es)	2015-05-19	2016-12-30	Glaxosmithkline Ip Dev Ltd	Amidas heterocíclicas como inhibidores de quinasa
CN105890945A (zh)	2016-04-01	2016-08-24	中国热带农业科学院分析测试中心	超声离心渗液进样快速测定土壤中速效钾的方法
WO2018183367A1 (en)	2017-03-28	2018-10-04	Van Goor Fredrick F	Methods of treating cystic fibrosis in patients with residual function mutations

2011
- 2011-04-07 CN CN201710033760.6A patent/CN106943403A/zh active Pending
- 2011-04-07 SI SI201132009T patent/SI3150198T1/sl unknown
- 2011-04-07 NZ NZ708598A patent/NZ708598A/en unknown
- 2011-04-07 EP EP21197971.1A patent/EP4005559B1/en active Active
- 2011-04-07 CN CN201710589819.XA patent/CN107260692A/zh active Pending
- 2011-04-07 WO PCT/US2011/031519 patent/WO2011127241A2/en not_active Ceased
- 2011-04-07 MX MX2012011656A patent/MX364937B/es active IP Right Grant
- 2011-04-07 LT LTEP16185289.2T patent/LT3150198T/lt unknown
- 2011-04-07 RS RS20211541A patent/RS62767B1/sr unknown
- 2011-04-07 MX MX2018014775A patent/MX379946B/es unknown
- 2011-04-07 JP JP2013503939A patent/JP2013523833A/ja active Pending
- 2011-04-07 NZ NZ602838A patent/NZ602838A/en unknown
- 2011-04-07 PL PL16185289T patent/PL3150198T3/pl unknown
- 2011-04-07 ES ES21197971T patent/ES3017582T3/es active Active
- 2011-04-07 RU RU2012147272/15A patent/RU2592368C2/ru active
- 2011-04-07 SM SM20210670T patent/SMT202100670T1/it unknown
- 2011-04-07 EP EP11715637.2A patent/EP2555755B2/en active Active
- 2011-04-07 HU HUE16185289A patent/HUE056525T2/hu unknown
- 2011-04-07 ES ES16185289T patent/ES2900353T3/es active Active
- 2011-04-07 AU AU2011237601A patent/AU2011237601B2/en active Active
- 2011-04-07 AR ARP110101172A patent/AR081760A1/es not_active Application Discontinuation
- 2011-04-07 US US13/081,750 patent/US8552034B2/en active Active
- 2011-04-07 PT PT161852892T patent/PT3150198T/pt unknown
- 2011-04-07 DK DK16185289.2T patent/DK3150198T3/da active
- 2011-04-07 EP EP16185289.2A patent/EP3150198B1/en active Active
- 2011-04-07 CN CN2011800279601A patent/CN102917692A/zh active Pending
- 2011-04-07 CA CA2795804A patent/CA2795804C/en active Active
- 2011-04-07 BR BR112012026255A patent/BR112012026255A2/pt not_active Application Discontinuation
- 2011-04-07 HR HRP20211752TT patent/HRP20211752T1/hr unknown
- 2011-04-07 ES ES11715637T patent/ES2604480T5/es active Active
2012
- 2012-10-05 US US13/646,130 patent/US20130095181A1/en not_active Abandoned
- 2012-10-09 IL IL222314A patent/IL222314A/en active IP Right Grant
- 2012-11-01 ZA ZA2012/08225A patent/ZA201208225B/en unknown
2013
- 2013-09-19 US US14/031,360 patent/US20140023706A1/en not_active Abandoned
2014
- 2014-11-14 US US14/542,396 patent/US9241934B2/en active Active
2016
- 2016-01-14 JP JP2016005254A patent/JP2016128454A/ja active Pending
- 2016-01-19 US US15/001,036 patent/US10076513B2/en active Active
2017
- 2017-04-09 IL IL251662A patent/IL251662A0/en unknown
- 2017-12-07 JP JP2017234962A patent/JP2018058886A/ja active Pending
2018
- 2018-07-31 US US16/050,029 patent/US20190070155A1/en not_active Abandoned
2019
- 2019-08-02 US US16/530,240 patent/US11052075B2/en active Active
2021
- 2021-05-28 US US17/333,478 patent/US20220031679A1/en not_active Abandoned
- 2021-12-03 CY CY20211101061T patent/CY1124852T1/el unknown

Also Published As

Publication number	Publication date
US20220031679A1 (en)	2022-02-03
EP4005559A1 (en)	2022-06-01
RU2012147272A (ru)	2014-05-20
US20130095181A1 (en)	2013-04-18
US20190070155A1 (en)	2019-03-07
MX2012011656A (es)	2012-11-23
HRP20211752T1 (hr)	2022-02-18
JP2013523833A (ja)	2013-06-17
US9241934B2 (en)	2016-01-26
US11052075B2 (en)	2021-07-06
RU2592368C2 (ru)	2016-07-20
US20200197380A1 (en)	2020-06-25
DK3150198T3 (da)	2021-11-01
NZ708598A (en)	2017-05-26
ES2604480T5 (es)	2020-03-17
CN102917692A (zh)	2013-02-06
RS62767B1 (sr)	2022-01-31
JP2016128454A (ja)	2016-07-14
WO2011127241A3 (en)	2012-02-02
NZ602838A (en)	2015-06-26
US20140023706A1 (en)	2014-01-23
IL251662A0 (en)	2017-06-29
US10076513B2 (en)	2018-09-18
US8552034B2 (en)	2013-10-08
US20160303096A1 (en)	2016-10-20
EP2555755B1 (en)	2016-08-24
SI3150198T1 (sl)	2021-11-30
IL222314A (en)	2017-04-30
MX364937B (es)	2019-05-15
AU2011237601B2 (en)	2015-08-20
PL3150198T3 (pl)	2022-01-17
EP2555755B2 (en)	2019-07-10
AU2011237601A1 (en)	2012-11-01
ZA201208225B (en)	2013-07-31
EP3150198B1 (en)	2021-09-22
US20110256220A1 (en)	2011-10-20
ES2900353T3 (es)	2022-03-16
CN106943403A (zh)	2017-07-14
EP3150198A1 (en)	2017-04-05
JP2018058886A (ja)	2018-04-12
BR112012026255A2 (pt)	2017-03-14
HUE056525T2 (hu)	2022-02-28
MX379946B (es)	2025-03-11
SMT202100670T1 (it)	2022-01-10
US20150140094A1 (en)	2015-05-21
CN107260692A (zh)	2017-10-20
ES2604480T3 (es)	2017-03-07
IL222314A0 (en)	2012-12-31
WO2011127241A2 (en)	2011-10-13
CA2795804C (en)	2021-10-26
EP2555755A2 (en)	2013-02-13
CY1124852T1 (el)	2022-11-25
PT3150198T (pt)	2021-12-22
EP4005559B1 (en)	2025-02-26
AR081760A1 (es)	2012-10-17
CA2795804A1 (en)	2011-10-13
ES3017582T3 (en)	2025-05-13

Publication	Publication Date	Title
LT3150198T (lt)	2021-12-10	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
IL250259A0 (en)	2017-03-30	Compositions comprising ursolic acid and derivatives thereof and uses thereof
HUE048859T2 (hu)	2020-08-28	Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk
IL214822A0 (en)	2011-11-30	Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EP2604260A4 (en)	2015-01-07	NOVEL HETEROCYCLIC DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
IL224288A (en)	2015-02-26	Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
PT2806859T (pt)	2019-09-04	Formulações de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
IL216006A (en)	2015-03-31	Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
LT3222272T (lt)	2021-12-27	Farmacinė karbetocino kompozicija
IL224544B (en)	2018-07-31	Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
IL218137A (en)	2016-06-30	Annotated 4-Benzamido Benzoic Acid, Preparations Containing and Using It for the Preparation of Medicines
FI20135146L (fi)	2013-02-15	Farmaseuttiset koostumukset ja hoitomenetelmät
BRPI0918206A2 (pt)	2015-12-08	derivados de animoéster e composição medicinal destes
BRPI1007413A2 (pt)	2015-08-25	Composição compreendendo ácido caftárico e/ou seus derivados
BRPI1007194A2 (pt)	2015-08-25	Composição compreendendo ácido chicórico e/ou derivados do mesmo
FI20135152L (fi)	2013-02-21	Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
IL220998A0 (en)	2012-09-24	Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as phamaceuticals
PL2651409T3 (pl)	2017-05-31	Nowa kompozycja farmaceutyczna zawierająca nlpz i cyklodekstrynę
PL2619007T3 (pl)	2019-07-31	Produkt zawierający bakterie kwasu mlekowego i środek osuszający
IL226003A0 (en)	2013-06-27	Derivation of trans-2-decenoic acid and a pharmaceutical agent containing it
LT2320739T (lt)	2020-01-27	Farmacinės kompozicijos ir jų stabilizavimo būdai
SMT201500005B (it)	2015-05-05	Composizione framaceutica inalabile
EE201300004A (et)	2013-08-15	Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
BRPI0818702A2 (pt)	2015-04-22	Formulação farmacêutica de ácido clavulânico
ATE537172T1 (de)	2011-12-15	Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel